The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy by Jin Li, Yuhong Ma, Qixuemeng Wu, Pengbin Ping, Juan Li, Xiaoying Xu

Subjects: Get full text

The expression of BHLHE22 in endometrial carcinoma: Associations with mismatch repair protein expression status, tumor-infiltrating immune cells, programmed death-ligand 1 and clin... by Lin-Yu Chen, Hsing-Yu Chen, Hung-Cheng Lai, Shiou-Fu Lin, Kuo-Chang Wen, Darmawi, Phui-Ly Liew

Subjects: Get full text

Rhaponticin suppresses the stemness phenotype of gastric cancer stem-like cells CD133+/CD166 + by inhibiting programmed death-ligand 1 by Yulong Li, Yu Zhang, Jialin Tang

Subjects: Get full text

The contribution of the CRP/CD64 axis to renal cancer progression by inducing protumor activation of tumor‐associated macrophages by Cheng Pan, Yukio Fujiwara, Hiromu Yano, Toshiki Anami, Yuki Ibe, Lianbo Li, Yuji Miura, Takanobu Motoshima, Shigeyuki Esumi, Junji Yatsuda, Taizo Hibi, Tomomi Kamba, Yoshihiro Komohara

Subjects: Get full text

Immune Checkpoint Inhibitor-Associated Celiac Disease: A Retrospective Analysis and Literature Review by Malvika Gupta, Christopher Graham, Supriya Gupta

Subjects: Get full text

A minimalist multifunctional nano-prodrug for drug resistance reverse and integration with PD-L1 mAb for enhanced immunotherapy of hepatocellular carcinoma by Ting Zou, Yun Huang, Zongtao Zhou, Shuangyan He, Jia Liu, Yalan Chen, Hongdu Liu, Zhonghui Luo, Miaoxin Liu, Hua Wei, CuiYun Yu

Subjects: Get full text

The Prognostic Value of Serum Soluble Programmed Death 1 (sPD‐1) and Programmed Death Ligand 1 (sPD‐L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis... by Qiyao Yu, Jie Li, Wenjie Mao, Zheng Li, Xuan Li, Bin Li

Subjects: Get full text

IGF2BP1 accelerates the aerobic glycolysis to boost its immune escape in hepatocellular carcinoma microenvironment by Xuxing Ye, Junmei Lin, Yanping Chen, Xiaobo Wang

Subjects: Get full text

Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease by Katie Meehan, Connull Leslie, Michaela Lucas, Angela Jacques, Bob Mirzai, James Lim, Max Bulsara, Yasir Khan, Nicholas C. Wong, Benjamin Solomon, Chady Sader, Peter Friedland, Gisela Mir Arnau, Timothy Semple, Annette M. Lim

Subjects: Get full text

Evaluation of prognostic significance of histopathological characteristics and tumor-infiltrating lymphocytes for pancreatic cancer survival by Kadir Çorbacı, Meryem Gunay Gurleyik, Aylin Gonultas, Fugen Aker, Mehmet Onur Gul, Metin Tilki

Subjects: Get full text

Serum assisted PD-L1 aptamer screening for improving its stability by Yu Zhou, Haozhe Zhang, Yujing Ding, Changyuan Yu, Hao Li

Subjects: Get full text

NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma by Chao-Yan Yao, Hang-Tian Tao, Jin-Jin He, Feng-Yi Zhu, Cui-Qing Xie, Yu-Na Cheng, Ji-Qin Li, Zhuang-Zhuang Liu, Chun-Yu Hou, Xue-Li Liu, Yong-Li Fan, Dong Fang, Xin-Rui Lv

Subjects: Get full text

PEGylated Elesclomol@Cu(Ⅱ)-based Metal‒organic framework with effective nanozyme performance and cuproptosis induction efficacy for enhanced PD-L1-based immunotherapy by Xufeng Lu, Wenhai Deng, Shuaibin Wang, Shengsheng Zhao, Bingzi Zhu, Binglong Bai, Yiwen Mao, Ji Lin, Yongdong Yi, Zuoliang Xie, Xiang Wang, Yongyong Lu, Xiufeng Huang, Tao You, Xiaolei Chen, Weijian Sun, Xian Shen

Subjects: Get full text

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials by Ji Ren, Jinghe Wang, Yanan Wang, Dongying Yang, Jianming Sheng, Shili Zhu, Yunli Liu, Xiaoqi Li, Wei Liu, Binbin Zhang

Subjects: Get full text

Network Medicine‐Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD‐L1 Expression via Targeting SPOP in Cancer by Saisai Tian, Mengting Xu, Xiangxin Geng, Jiansong Fang, Hanchen Xu, Xinying Xue, Hongmei Hu, Qing Zhang, Dianping Yu, Mengmeng Guo, Hongwei Zhang, Jinyuan Lu, Chengyang Guo, Qun Wang, Sanhong Liu, Weidong Zhang

Subjects: Get full text

Oncogene mutations in non-small cell lung cancer patients in Iran: a study of their association with programmed death ligand-1 expression by Zahra Abrehdari-Tafreshi, Majid Pirestani, Zahra Mosaferi, Nasser Rakhshani, Ehsan Arefian

Subjects: Get full text

PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy... by Yuka Suzuki, Kei Kohno, Kosei Matsue, Ayako Sakakibara, Eri Ishikawa, Satoko Shimada, Kazuyuki Shimada, Seiyo Mabuchi, Taishi Takahara, Seiichi Kato, Shigeo Nakamura, Akira Satou

Subjects: Get full text

Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors by Qi Zhang, Jialing Chen, Nana Tsai, Xuejuan Zhu, Minyan Zhao, Lirong Meng, Pedro Fong

Subjects: Get full text

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma by Ziting Peng, Jianhui Dong, Shuyao Tang, Jiaxu Shi, Tongdong Shi

Subjects: Get full text

Dissecting the link between PD-1/PD-L1-based immunotherapy and cancer pain: mechanisms, research implications, and artificial intelligence perspectives by Marco Cascella, Brigida Miranda, Carmen Gagliardi, Lucia Santaniello, Milena Mottola, Alida Mancusi, Laura Ferrara, Federica Monaco, Francesca Gargano, Francesco Perri, Alessandro Ottaiano, Maurizio Capuozzo, Ornella Piazza, Stefano Pepe, Anna Crispo, Agostino Guida, Giovanni Salzano, Giustino Varrassi, Luigi Liguori, Francesco Sabbatino, The TRIAL Group

Subjects: Get full text